Lipocine Financial Statements
Lipocine Financial Overview
Lipocine's market cap is currently ―. The company's EPS TTM is $-0.01; its P/E ratio is -94.24; Lipocine is scheduled to report earnings on August 10, 2022, and the estimated EPS forecast is $-0.04. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 16.09M | $ 54.99K | $ 0.00 | $ 0.00 |
| Gross Profit | $ ― | $ 13.83M | $ -2.31M | $ -1.46M | $ ― |
| EBIT | $ -3.47M | $ 12.66M | $ -3.04M | $ -6.75M | $ -3.30M |
| EBITDA | $ -3.47M | $ 12.66M | $ -3.04M | $ -6.75M | $ -3.30M |
| Net Income Common Stockholders | $ -3.49M | $ 12.62M | $ -3.08M | $ -6.81M | $ -3.37M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 18.80M | $ 19.67M | $ 38.66M | $ 42.00M | $ 44.62M |
| Total Assets | $ 47.60M | $ 52.48M | $ 40.39M | $ 47.18M | $ 50.58M |
| Total Debt | $ 2.92M | $ 4.57M | $ 6.29M | $ 3.21M | $ 3.33M |
| Net Debt | $ -15.88M | $ -15.10M | $ -32.38M | $ -38.79M | $ -41.28M |
| Total Liabilities | $ 5.19M | $ 6.91M | $ 7.58M | $ 11.43M | $ 8.19M |
| Stockholders Equity | $ 14.51M | $ 15.34M | $ 32.81M | $ 35.75M | $ 42.39M |
| Cash Flow | |||||
| Free Cash Flow | $ -3.91M | $ 8.99M | $ -6.98M | $ -2.36M | $ -4.06M |
| Operating Cash Flow | $ -3.89M | $ 8.99M | $ -6.98M | $ -2.36M | $ -4.06M |
| Investing Cash Flow | $ 7.30M | $ -9.72M | $ 1.37M | $ -1.43M | $ -33.99M |
| Financing Cash Flow | $ -627.35K | $ -838.46K | $ -838.26K | $ -838.61K | $ 29.44M |